At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
Losartandrug
Likely dose
Losartan 0.7mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Children's Hospital Medical Center, Cincinnati·interventional·Posted Nov 24, 2011·Updated Sep 29, 2020
In Brief
A Phase 2 clinical trial evaluating Losartan for Nephropathy and Sickle Cell Anemia. Completed, enrolled 36 participants across 9 sites.
Detailed Summary
Sickle cell disease causes kidney damage with increasing age, leading to chronic kidney disease and renal failure in nearly one third of patients with sickle cell disease. Currently, there is no treatment for sickle cell related kidney disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNephropathy, Sickle Cell Anemia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 2011
Enrollment StartFeb 2012
Primary CompletionNov 2015
Study CompletionDec 2015
TodayJul 2026
First PostedNov 24, 2011
Enrollment StartFeb 1, 2012
Primary CompletionNov 1, 2015
Study CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 14.6 years ago
Interventions
Losartandrug
Form: suspension, tablet. Dosage \& frequency: age 6-16 = 0.7mg/kg once daily; age \>16 = 50mg once daily. Duration: 6 months